Form 4: Agios CCO Sells Shares for Tax After PSU Vesting

Agios Pharmaceuticals' Chief Commercial Officer, Tsveta Milanova, sold shares to cover tax obligations following the vesting of performance share units tied to a regulatory milestone.

Summary

• Tsveta Milanova, Chief Commercial Officer of Agios Pharmaceuticals, Inc. (AGIO), reported transactions involving the company's common stock and performance share units (PSUs).
• On December 30, 2025, Milanova acquired 6,000 shares of common stock at a price of $0, resulting from the vesting of performance share units.
• Concurrently, she disposed of 2,932 shares of common stock at a price of $27.09 per share.
• The sale of shares was executed to cover tax withholding obligations related to the vesting of her performance share units.
• This transaction was pre-planned and conducted pursuant to durable automatic sale instructions consistent with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• Following these transactions, Milanova beneficially owns 29,190 shares of common stock.
• The performance share units, granted on March 1, 2023, vested as to 50% of the underlying shares upon the achievement of a specified regulatory milestone, which was determined to have been met on December 29, 2025.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive. The vesting of performance share units due to a regulatory milestone achievement is a positive operational indicator. The subsequent sale of shares is a routine, pre-planned event for tax purposes, not a discretionary sale indicating a lack of confidence.

Positives

• The vesting of performance share units indicates the successful achievement of a specified regulatory milestone, reflecting progress in the company's development pipeline or strategic objectives.

Negatives

• A portion of the vested shares was sold, reducing the reporting person's direct beneficial ownership, although this was for tax purposes and pre-planned.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide specific details to analyze broader industry trends or competitive landscape. However, the achievement of a regulatory milestone, which triggered the PSU vesting, could be indicative of progress within the biotechnology or pharmaceutical sector, where such milestones are critical for product development and market entry.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Commercial Officer is a routine event for tax purposes and is unlikely to significantly impact shareholder sentiment or the company's valuation, especially given it was pre-planned. The achievement of a regulatory milestone, however, could be viewed positively as it indicates progress in the company's pipeline.
• Employees: The vesting of performance share units for an executive demonstrates the company's compensation structure and the achievement of internal performance goals, which can be a positive signal for employee morale regarding company performance.

Next Steps

• Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Key Dates

Keywords

AGIO, Agios Pharmaceuticals, Insider Transaction, Form 4, Performance Share Units, Stock Sale, Tax Withholding, Rule 10b5-1, Chief Commercial Officer